Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 6;9(10):2104.
doi: 10.3390/microorganisms9102104.

Virulence Potential and Treatment Options of Multidrug-Resistant (MDR) Acinetobacter baumannii

Affiliations
Review

Virulence Potential and Treatment Options of Multidrug-Resistant (MDR) Acinetobacter baumannii

Sunil Kumar et al. Microorganisms. .

Abstract

Acinetobacter baumannii is an opportunistic pathogen which is undoubtedly known for a high rate of morbidity and mortality in hospital-acquired infections. A. baumannii causes life-threatening infections, including; ventilator-associated pneumonia (VAP), meningitis, bacteremia, and wound and urinary tract infections (UTI). In 2017, the World Health Organization listed A. baumannii as a priority-1 pathogen. The prevalence of A. baumannii infections and outbreaks emphasizes the direct need for the use of effective therapeutic agents for treating such infections. Available antimicrobials, such as; carbapenems, tigecycline, and colistins have insufficient effectiveness due to the appearance of multidrug-resistant strains, accentuating the need for alternative and novel therapeutic remedies. To understand and overcome this menace, the knowledge of recent discoveries on the virulence factors of A. baumannii is needed. Herein, we summarized the role of various virulence factors, including; outer membrane proteins, efflux pumps, biofilm, penicillin-binding proteins, and siderophores/iron acquisition systems. We reviewed the recent scientific literature on different A. baumannii virulence factors and the effective antimicrobial agents for the treatment and management of bacterial infections.

Keywords: Acinetobacter baumannii; Gram-negative bacteria; animal models; antibiotic therapy; mechanism of action; multidrug resistance; virulence factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Pathobiology of A. baumannii.
Figure 2
Figure 2
Potential virulence factors of A. baumannii.
Figure 3
Figure 3
Therapeutic treatment options for nosocomial infections of A. baumannii.

References

    1. Lin M.F., Lin Y.Y., Yeh H.W., Lan C.Y. Role of the BaeSR two-component system in the regulation of Acinetobacter baumannii adeAB genes and its correlation with tigecycline susceptibility. BMC Microbiol. 2014;14:119. doi: 10.1186/1471-2180-14-119. - DOI - PMC - PubMed
    1. Chan J.Z., Halachev M.R., Loman N.J., Constantinidou C., Pallen M.J. Defining bacterial species in the genomic era: Insights from the genus Acinetobacter. BMC Microbiol. 2012;12:302. doi: 10.1186/1471-2180-12-302. - DOI - PMC - PubMed
    1. Perez S., Innes G.K., Walters M.S., Mehr J., Arias J., Greeley R., Chew D. Increase in Hospital-Acquired Carbapenem-Resistant Acinetobacter baumannii Infection and Colonization in an Acute Care Hospital During a Surge in COVID-19 Admissions—New Jersey, February–July 2020. MMWR Morb. Mortal Wkly. Rep. 2020;69:1827–1831. doi: 10.15585/mmwr.mm6948e1. - DOI - PMC - PubMed
    1. Shu H., Li L., Wang Y., Guo Y., Wang C., Yang C., Gu L., Cao B. Prediction of the Risk of Hospital Deaths in Patients with Hospital-Acquired Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii Infection: A Multi-Center Study. Infect. Drug Resist. 2020;13:4147–4154. doi: 10.2147/IDR.S265195. - DOI - PMC - PubMed
    1. Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: Emergence of a successful pathogen. Clin. Microbiol. Rev. 2008;21:538–582. doi: 10.1128/CMR.00058-07. - DOI - PMC - PubMed

LinkOut - more resources